In the same way that BPC-157 is monitored, clinicians will keep tabs on symptoms, functional progress, mobility, and periodic test findings to ensure the treatment remains appropriate and is producing the desired results
Chandran A, Rosenheim J, Nageswaran G, Swadling L, Pollara G, Gupta RK, et al
Additionally, for the organic acidemias, methylmalonic and propionic acidemia (OMIM 251000 and 606054, respectively), monthly prophylactic treatment with the antibiotic metronidazole is also commonly used to reduce intestinal bacteria and the affiliated production of propionate, and this may confer the unexpected benefit of reducing TMAO production as well (Thompson et al
Robert Kushner: Well, I'm going to give you one more clinician perspective and then I'll answer your question
Our primary outcome was change in HbA 1c from baseline